Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial (British Journal of Cancer, (2019), 120, 10, (959-967), 10.1038/s41416-019-0435-4)

Ribi K.; Luo W.; Colleoni M.; Karlsson P.; Chirgwin J.; Aebi S.; Jerusalem G.; Neven P.; Di Lauro V.; Gomez H.L.; Ruhstaller T.; Abdi E.; Biganzoli L.; Müller B.; Barbeaux A.; Graas M.-P.; Rabaglio M.; Francis P.A.; Foukakis T.; Pagani O.; Graiff C.; Vorobiof D.; Maibach R.; Di Leo A.; Gelber R.D.; Goldhirsch A.; Coates A.S.; Regan M.M.; Bernhard J. · British Journal of Cancer (2020) · DOI: 10.1038/s41416-019-0709-x

Resumen

The ClinicalTrials.gov Identifier was incorrectly listed as NCT00651456. The correct identifier is listed below. Clinical trial information Clinical trial information: NCT00553410.